| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10238640 | GLAXOSMITHKLINE | Pharmaceutical suspension composition |
May, 2024
(7 months from now) | |
Children'S Advil Allergy Sinus is owned by Glaxosmithkline.
Children'S Advil Allergy Sinus contains Chlorpheniramine Maleate; Ibuprofen; Pseudoephedrine Hydrochloride.
Children'S Advil Allergy Sinus has a total of 1 drug patent out of which 0 drug patents have expired.
Children'S Advil Allergy Sinus was authorised for market use on 24 February, 2004.
Children'S Advil Allergy Sinus is available in suspension;oral dosage forms.
The generics of Children'S Advil Allergy Sinus are possible to be released after 25 May, 2024.
Market Authorisation Date: 24 February, 2004
Treatment: NA
Dosage: SUSPENSION;ORAL
CHILDREN'S ADVIL ALLERGY SINUS family patents
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic